Assay and medicament

Patent metadata

Field	Value
Publication number	US-11339374-B2
Application number	US-201816230114-A
Country	US
Kind code	B2
Filing date	Dec 21, 2018
Priority date	Jan 16, 2014
Publication date	May 24, 2022
Grant date	May 24, 2022

Abstract

The invention relates to defective interfering viruses and defective interfering virus RNAs that are effective as antiviral agents. The invention also relates to methods for identifying defective interfering virus RNAs that can be used as effective antiviral agents.

First claim

The invention claimed is:

1. A method to identify an antiviral agent, comprising:
in a host cell, exposing an influenza A virus to a test defective interfering (DI) influenza A virus RNA having a deletion in one of RNA segments 1, 2, or 3;
monitoring for the production of RNA from each of segments 1, 2, and 3 of the influenza A virus in the presence of the test DI influenza A virus RNA; and
identifying the antiviral agent as being a test DI virus RNA that interferes with production of RNA from each of segments 1, 2, and 3 of the influenza A virus.

2. The method according to claim 1 , wherein the RNA production from each of segments 1, 2 and 3 of the influenza A virus is monitored in a separate assay.

3. The method according to claim 1 , wherein the RNA production from each of segments 1, 2, or 3 of the influenza A virus comprises cRNA, mRNA and/or vRNA.

4. The method according to claim 3 , wherein both cRNA and mRNA production are monitored.

5. The method according to claim 1 , wherein one or more of segments 1, 2 or 3 of the influenza A virus is provided as a construct.

6. The method according to claim 5 , wherein the host cell is transfected with one or more nucleic acids each comprising one or more of segments 1, 2, and 3 of the influenza A virus.

7. The method according to claim 5 , wherein each of said segments 1, 2, and 3 of the influenza A virus is provided on a separate plasmid.

8. The method according to claim 5 , wherein the construct comprises a reporter gene, such that a reduction in production of RNA from a segment reduces expression of the reporter gene.

Assignees

• Univ Warwick

Inventors

• Dimmock Nigel J
• Easton Andrew J

Classifications

• C12N7/045 Primary

  Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered · CPC title

• C12N2760/16132

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• A61K35/76 Primary

  Viruses; Subviral particles; Bacteriophages · CPC title

• C12N2320/10

  in screening processes · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title